RxDoctor Payments Data

Anamika Katoch, MD

Hematology & Oncology · Fort Myers, FLNPI 1194938324

Payments from drug & device makers

$226,286in general payments, 2019–2025

Across 477 payments — averaging $474.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$206K
  • Gilead$5K
  • Avyxa Pharma, LLC$4K
  • AstraZeneca$3K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Puma Biotechnology, Inc.$1K
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$14,8887%
  • Speaking & faculty fees$172,81877%
  • Travel & lodging$28,60713%
  • Food & beverage$8,9044%
  • Education$2090%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$226,286 in reported general payments places this provider in the 70th percentile of 694 hematology & oncology providers in Florida.

See all hematology & oncology providers in Florida

Medicare billing

Part B allowed, 2024
$27,864
Medicare patients
131
Services billed
293

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lenalidomide26$393,467
RevlimidLenalidomide21$359,420
VerzenioAbemaciclib12$188,563
KisqaliRibociclib Succinate13$170,685
ErleadaApalutamide13$159,497
CalquenceAcalabrutinib Maleate15$145,496
TasignaNilotinib Hcl11$107,150
EliquisApixaban13$7,591
Fentanyl14$1,562
Ondansetron Hcl28$960
Anastrozole50$817
Hydroxyurea25$799
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen22$401
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen11$381
Dexamethasone17$380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$41$359,42021 claims
NovartisKisqali, Tasigna$66$277,83524 claims
Lilly USA, LLCVerzenio$205,817$188,56312 claims
Johnson & JohnsonErleada$97$159,49713 claims
AstraZenecaCalquence$3,005$145,49615 claims
PfizerEliquis$197$7,59113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 694 hematology & oncology providers in Florida.

Other hematology & oncology in Fort Myers

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →